


# EMERGE LAA POST-APPROVAL STUDY:



## PRESENTATIONS AND PUBLICATIONS YEAR-IN-REVIEW



**NCDR LAAO REGISTRY**  
EMERGE LAA CAPTURES  
REAL-WORLD AMULET  
LAAO PROCEDURE DATA



**2 YEARS**  
TRACKING FROM  
IMPLANT TO  
STUDY ENDPOINT



**~12,000 PATIENTS**  
IMPLANTED BETWEEN  
AUGUST 2021 AND  
DECEMBER 2023

**AF**  
SYMPOSIUM



### FIRST EXPERIENCE<sup>1</sup>

Amulet LAA Occluder demonstrates a favorable safety profile with a high rate of **acute implant success**, **complete closure**, and **freedom from OACs** through 45 days during early US commercial experience.

**CRT**

### LEARNING CURVE<sup>2</sup>

Implants across all levels of experience demonstrate **high procedural success rate** and **complete closure**. However, as implanter experience increases, **procedural success rates** improve, along with **lowered adverse events**.



**HeartRhythm**

### IMPLANT SUCCESS AFTER PRIOR FAILED WATCHMAN LAAC ATTEMPT<sup>3</sup>

When Watchman 2.5<sup>+</sup> or Watchman FLX<sup>+</sup> LAAC **implantation fails**, the Amulet LAA Occluder delivers a high degree of **implant success** and **closure** and a **low rate of adverse events**.

**CRF**  
**TCT**

### ONE-YEAR OUTCOMES<sup>4</sup>

EMERGE LAA one-year outcomes for the **first 5600 patients** demonstrate **safety** and **effectiveness** of the Amulet LAA Occluder in the real-world setting, consistent with the randomized controlled Amulet IDE Trial.

#### References

1. Alkhouli, M, Freeman, J, Ellis, C. et al. First Experience With Amulet in the United States: Early Insights From EMERGE LAA Postapproval Study. J Am Coll Cardiol Interv. 2024 Feb, 17 (3) 422-434.
2. Shah, A. et al. Learning Curve and Outcomes with the Amulet Occluder within the EMERGE LAA Post-Approval Study. CRT 2024
3. Makkar A, Alkhouli M, Ellis C. et al. Feasibility of Amulet occluder implantation after failed left atrial appendage occlusion attempt: Insights from the EMERGE LAA postapproval study. Heart Rhythm. 2024 Nov;21(11):2126-2135.
4. Shah et al. One-Year Real-World Outcomes With the Amulet Occluder From the EMERGE LAA Post-Approval Study. TCT 2024

**CAUTION:** Product(s) intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use inside the product carton (when available) or at <https://www.eifu.abbott/> for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Information contained herein for **DISTRIBUTION outside of the U.S. ONLY**.  
Always check the regulatory status of the device in your region.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.  
Photo(s) on file at Abbott.

#### Abbott

3200 Lakeside Dr., Santa Clara, CA 95054 USA

™ Indicates a trademark of the Abbott group of companies.

‡ Indicates a third-party trademark, which is property of its respective owner.

[www.structuralheart.abbott](http://www.structuralheart.abbott)

© 2025 Abbott. All rights reserved. MAT-2500543 v1.0 | Item approved for OUS use only.

